See the DrugPatentWatch profile for Yupelri
The cost of Yupelri generics is not yet publicly available. Yupelri, also known by its generic name aclidinium bromide, is an inhaled medication used to treat bronchospasm in patients with chronic obstructive pulmonary disease (COPD) [1].
When could Yupelri generics become available?
The patent for Yupelri is set to expire in June 2028 [2]. However, this date could change due to patent challenges or other legal actions. Generic versions of a drug typically become available after the expiration of its primary patents, though in some cases, they can be launched earlier through settlement agreements or court rulings [3].
How do generic drug prices compare to brand-name drugs?
Generic drugs are generally priced significantly lower than their brand-name counterparts. This price difference is primarily due to the reduced research and development costs associated with generic manufacturing. Companies that produce generics do not need to conduct the extensive clinical trials required for new drug approval, as they only need to demonstrate bioequivalence to the original drug [4].
What factors influence the cost of COPD medications?
The cost of COPD medications like Yupelri and its potential generics can be influenced by several factors. These include the complexity of the drug's manufacturing process, the number of generic manufacturers entering the market, insurance formulary placement, and any available patient assistance programs [5]. The pricing of inhaled medications can also be affected by the delivery device and the specific formulation of the drug [6].
What is Yupelri used for?
Yupelri is prescribed as a maintenance treatment to prevent bronchospasm in adults with COPD [1]. It works by relaxing the muscles around the airways, making it easier to breathe [7].
Who manufactures Yupelri?
Yupelri is manufactured by Mylan, a subsidiary of Viatris [1].
Sources:
[1] https://www.yupelri.com/
[2] https://drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/blog/understanding-drug-patent-expiration-and-generic-entry
[4] https://www.fda.gov/drugs/generic-drugs/introduction-generic-drugs
[5] https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treatment
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766073/
[7] https://www.yupelri.com/how-yupelri-works